Fairmont Diagnostics

Fairmont Diagnostics is a molecular diagnostics company that originated as a spin-out from the University of Pennsylvania. The company is dedicated to developing blood-based diagnostic tools for the early detection and risk stratification of prostate cancer. Its core technology utilizes a proprietary panel of biomarkers designed to differentiate between aggressive, high-risk tumors and indolent, low-risk cases that may not require immediate intervention. By providing more granular data than the standard prostate-specific antigen (PSA) test, Fairmont aims to reduce the incidence of unnecessary biopsies and the over-treatment of patients. The company has previously received funding from regional investors such as Ben Franklin Technology Partners to advance its clinical validation efforts.